NCT01636128View on ClinicalTrials.gov

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms
Interventions
DRUG

difluoromethylornithine

500 mg oral for 14 days, combined with sulindac for 15 days

DRUG

Sulindac

150 mg oral for 15 days, combined with DFMO for 14 days

Sponsors
All Listed Sponsors
collaborator

University of Arizona

OTHER

lead

Cancer Prevention Pharmaceuticals, Inc.

INDUSTRY